Idoia Bilbao-Meseguer1, Alicia Rodríguez-Gascón2, Helena Barrasa3, Arantxazu Isla4, María Ángeles Solinís5. 1. Department of Pharmacy, Cruces University Hospital, Plaza de Cruces 12, 48903, Barakaldo, Bizkaia, Spain. 2. Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Center, University of the Basque Country UPV/EHU, Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. 3. Intensive Care Unit, University Hospital of Alava, c/ Olaguibel no 29, Vitoria-Gasteiz, Spain. 4. Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Center, University of the Basque Country UPV/EHU, Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. arantxa.isla@ehu.eus. 5. Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, Lascaray Research Center, University of the Basque Country UPV/EHU, Paseo de la Universidad, 7, 01006, Vitoria-Gasteiz, Spain. marian.solinis@ehu.eus.
Abstract
BACKGROUND: Traditionally, renal function in critically ill patients has been assessed to identify renal dysfunction, and dose adjustment is generally accepted in such a context. Nevertheless, augmented renal clearance (ARC) is a less well-studied phenomenon that could lead to faster elimination of drugs, resulting in subtherapeutic concentrations and poorer clinical outcomes when standard dosage guidelines are followed. OBJECTIVE: The aim of this systematic review was to gather and summarise all the available evidence on ARC in critically ill patients, including its definition, underlying mechanisms, epidemiology, diagnosis and impact on both drug pharmacokinetics and clinical outcomes. METHOD: A systematic review was conducted to include all the original studies that provided information on ARC in critically ill patients, and is reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Augmented renal clearance, defined as a creatinine clearance (CrCl) > 130 mL/min/1.73 m2, preferably measured in urine, is present in 20-65% of critically ill patients. Younger age, polytrauma and lower severity illness have been identified as risk factors. An influence of ARC on antimicrobial pharmacokinetics has been observed, with ARC consistently being associated with subtherapeutic antibiotic plasma concentrations. CONCLUSION: ARC is a prevalent condition in critically ill patients, especially in young people, with urinary CrCl being the best diagnostic method because mathematical estimates tend to underestimate CrCl. ARC increases renal drug elimination and has a clear influence on certain antimicrobial plasma levels, but is yet to define its impact on clinical outcomes and on pharmacokinetics of other types of drugs. Research on the need to stage ARC and establish specific dosing guidelines is warranted.
BACKGROUND: Traditionally, renal function in critically ill patients has been assessed to identify renal dysfunction, and dose adjustment is generally accepted in such a context. Nevertheless, augmented renal clearance (ARC) is a less well-studied phenomenon that could lead to faster elimination of drugs, resulting in subtherapeutic concentrations and poorer clinical outcomes when standard dosage guidelines are followed. OBJECTIVE: The aim of this systematic review was to gather and summarise all the available evidence on ARC in critically ill patients, including its definition, underlying mechanisms, epidemiology, diagnosis and impact on both drug pharmacokinetics and clinical outcomes. METHOD: A systematic review was conducted to include all the original studies that provided information on ARC in critically ill patients, and is reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. RESULTS: Augmented renal clearance, defined as a creatinine clearance (CrCl) > 130 mL/min/1.73 m2, preferably measured in urine, is present in 20-65% of critically ill patients. Younger age, polytrauma and lower severity illness have been identified as risk factors. An influence of ARC on antimicrobial pharmacokinetics has been observed, with ARC consistently being associated with subtherapeutic antibiotic plasma concentrations. CONCLUSION: ARC is a prevalent condition in critically ill patients, especially in young people, with urinary CrCl being the best diagnostic method because mathematical estimates tend to underestimate CrCl. ARC increases renal drug elimination and has a clear influence on certain antimicrobial plasma levels, but is yet to define its impact on clinical outcomes and on pharmacokinetics of other types of drugs. Research on the need to stage ARC and establish specific dosing guidelines is warranted.
Authors: Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Jennifer H Martin; Ross Norris; Michael Barras; Jason Roberts; Ray Morris; Matthew Doogue; Graham R D Jones Journal: Clin Biochem Rev Date: 2010-02
Authors: Andrew A Udy; Paul Jarrett; Melissa Lassig-Smith; Janine Stuart; Therese Starr; Rachel Dunlop; Renae Deans; Jason A Roberts; Siva Senthuran; Robert Boots; Kavita Bisht; Andrew C Bulmer; Jeffrey Lipman Journal: J Neurotrauma Date: 2016-08-16 Impact factor: 5.269
Authors: Jeffrey F Barletta; Alicia J Mangram; Marilyn Byrne; Joseph F Sucher; Alexzandra K Hollingworth; Francis R Ali-Osman; Gina R Shirah; Michael Haley; James K Dzandu Journal: J Trauma Acute Care Surg Date: 2017-04 Impact factor: 3.313
Authors: Casey C May; Shaily Arora; Sara E Parli; Justin F Fraser; Melissa Thompson Bastin; Aaron M Cook Journal: Neurocrit Care Date: 2015-12 Impact factor: 3.210
Authors: Massimo Sartelli; Dieter G Weber; Etienne Ruppé; Matteo Bassetti; Brian J Wright; Luca Ansaloni; Fausto Catena; Federico Coccolini; Fikri M Abu-Zidan; Raul Coimbra; Ernest E Moore; Frederick A Moore; Ronald V Maier; Jan J De Waele; Andrew W Kirkpatrick; Ewen A Griffiths; Christian Eckmann; Adrian J Brink; John E Mazuski; Addison K May; Rob G Sawyer; Dominik Mertz; Philippe Montravers; Anand Kumar; Jason A Roberts; Jean-Louis Vincent; Richard R Watkins; Warren Lowman; Brad Spellberg; Iain J Abbott; Abdulrashid Kayode Adesunkanmi; Sara Al-Dahir; Majdi N Al-Hasan; Ferdinando Agresta; Asma A Althani; Shamshul Ansari; Rashid Ansumana; Goran Augustin; Miklosh Bala; Zsolt J Balogh; Oussama Baraket; Aneel Bhangu; Marcelo A Beltrán; Michael Bernhard; Walter L Biffl; Marja A Boermeester; Stephen M Brecher; Jill R Cherry-Bukowiec; Otmar R Buyne; Miguel A Cainzos; Kelly A Cairns; Adrian Camacho-Ortiz; Sujith J Chandy; Asri Che Jusoh; Alain Chichom-Mefire; Caroline Colijn; Francesco Corcione; Yunfeng Cui; Daniel Curcio; Samir Delibegovic; Zaza Demetrashvili; Belinda De Simone; Sameer Dhingra; José J Diaz; Isidoro Di Carlo; Angel Dillip; Salomone Di Saverio; Michael P Doyle; Gereltuya Dorj; Agron Dogjani; Hervé Dupont; Soumitra R Eachempati; Mushira Abdulaziz Enani; Valery N Egiev; Mutasim M Elmangory; Paula Ferrada; Joseph R Fitchett; Gustavo P Fraga; Nathalie Guessennd; Helen Giamarellou; Wagih Ghnnam; George Gkiokas; Staphanie R Goldberg; Carlos Augusto Gomes; Harumi Gomi; Manuel Guzmán-Blanco; Mainul Haque; Sonja Hansen; Andreas Hecker; Wolfgang R Heizmann; Torsten Herzog; Adrien Montcho Hodonou; Suk-Kyung Hong; Reinhold Kafka-Ritsch; Lewis J Kaplan; Garima Kapoor; Aleksandar Karamarkovic; Martin G Kees; Jakub Kenig; Ronald Kiguba; Peter K Kim; Yoram Kluger; Vladimir Khokha; Kaoru Koike; Kenneth Y Y Kok; Victory Kong; Matthew C Knox; Kenji Inaba; Arda Isik; Katia Iskandar; Rao R Ivatury; Maurizio Labbate; Francesco M Labricciosa; Pierre-François Laterre; Rifat Latifi; Jae Gil Lee; Young Ran Lee; Marc Leone; Ari Leppaniemi; Yousheng Li; Stephen Y Liang; Tonny Loho; Marc Maegele; Sydney Malama; Hany E Marei; Ignacio Martin-Loeches; Sanjay Marwah; Amos Massele; Michael McFarlane; Renato Bessa Melo; Ionut Negoi; David P Nicolau; Carl Erik Nord; Richard Ofori-Asenso; AbdelKarim H Omari; Carlos A Ordonez; Mouaqit Ouadii; Gerson Alves Pereira Júnior; Diego Piazza; Guntars Pupelis; Timothy Miles Rawson; Miran Rems; Sandro Rizoli; Claudio Rocha; Boris Sakakushev; Miguel Sanchez-Garcia; Norio Sato; Helmut A Segovia Lohse; Gabriele Sganga; Boonying Siribumrungwong; Vishal G Shelat; Kjetil Soreide; Rodolfo Soto; Peep Talving; Jonathan V Tilsed; Jean-Francois Timsit; Gabriel Trueba; Ngo Tat Trung; Jan Ulrych; Harry van Goor; Andras Vereczkei; Ravinder S Vohra; Imtiaz Wani; Waldemar Uhl; Yonghong Xiao; Kuo-Ching Yuan; Sanoop K Zachariah; Jean-Ralph Zahar; Tanya L Zakrison; Antonio Corcione; Rita M Melotti; Claudio Viscoli; Perluigi Viale Journal: World J Emerg Surg Date: 2016-07-15 Impact factor: 5.469
Authors: Evelyn Dhont; Tatjana Van Der Heggen; Annick De Jaeger; Johan Vande Walle; Peter De Paepe; Pieter A De Cock Journal: Pediatr Nephrol Date: 2018-10-29 Impact factor: 3.714
Authors: Cui-Yao He; Pan-Pan Ye; Bin Liu; Lin Song; John van den Anker; Wei Zhao Journal: Antimicrob Agents Chemother Date: 2021-08-02 Impact factor: 5.191